Brexit May Delay Cancer Drugs For Two Years
Among a handful of problems caused as consequences of the recent separation of the UK from EU is the impending doom that Brexit may delay the availability of cancer drugs to patients who need it most. Patients could be forced to wait two years for new drugs due to the new political situation, experts warn. This is because the European Medicines Agency (EMA), which evaluates and approves new drug, will likely prioritize the much larger European market.
Jeremy Hunt, Health Secretary says that he does not expect the UK to remain within the European Medicines Agency after the political separation. A former chairman of the UK’s medical regulator also says that pharmaceutical companies now have to obtain separate licenses from EMA to market their products in Britain and in other European countries. It's likely that they will prioritize other larger European regions, and in this point of view, Brexit may delay the coming of new drugs in the UK for two years, the Mirror Online reports.
Furthermore, a drug company executive have suggested that the UK would be receiving the “second or third wave” for new drugs after Europe, the USA and Japan. Analysts estimate that the delays would run as much as 24 months. This situation could worsen the quality of care given to NHS patients who are already grappling with several health service issues.
Sir Alasdair Breckenridge, a former chairman of the UK’s Medicines and Healthcare products Regulatory Agency says that since the UK market is smaller compared to the European market, it is inevitable that there will be a delay in getting new drugs for patients in the United Kingdom. He adds that important drugs, including new cancer drugs could be among those affected. According to the BBC, aside from the fact that Brexit may delay the availability of drugs, medicine prices will also increase due to the second application costs, after the European application costs, that drug companies will have to pay.
Multiple Sclerosis May Stop In High-Risk Treatment
A new therapy for the incurable disease, Multiple Sclerosis, will use highly toxic drug cancers and a stem cell transplant to attempt to stop the sysmtoms for up to five years. However, due to its risky nature, only selected patients can try it.
Surface Book Increases By £150 In The UK, Brexit Is The One To Blame
Brexit is affecting how tech products are priced in the UK.
UK Will Be Having A 'Cyber Curriculum' To Defend Against Cyber Attacks
To the growing concern over the damage hackers and terrorists could inflict to the economy and infrastructure, the U.K. government has decided to add a cyber curriculum for teenagers aged between 14 and 18 years old.
By 2030 Robots May Take Jobs Of 250,000 Workers In UK
According to market analysts, in the U.K. around 250,000 public sector jobs could be lost to robots by the year 2030.
NHS Charges Foreign Patients Up Front
If you're a foreign patient in the UK, NHS charges you upfront before they give treatment for non-urgent medical problems. The new law is put into motion after damning reports of failure of health cost recovery surfaced last week.
MORE IN ITECHPOST
'Tokyo Ghoul' Season 3 Delayed By Its Live-Action Movie? Ken Kenaki Returns With Another Identity?
"Tokyo Ghoul" season 3's release is delayed and there are countless speculations as to why it is being pushed back. Reports claim that the show is to give way to "One Punch Man" and "My Hero Acdemia" but new rumors say that it's lack of materials and storyline as well as its live-action movie are causing the delay.